DEFA14A: Masimo Navigates Consumer Business Separation and Healthcare Growth Amidst Proxy Fight

Masimo is exploring options for its consumer business, including a joint venture or sale, while focusing on healthcare growth driven by strong census and contracting, all amidst a proxy battle with Politan Capital.

Summary

• Masimo participated in the 2024 Wells Fargo Healthcare Conference, where executives discussed the company's performance and strategic direction.
• The healthcare environment is stable with strong census growth, leading to 14% growth in consumables and service revenue in the first half of the year.
• Healthcare revenues grew nearly 10% year-to-date, and the company expects 10% growth for the full year, despite a down capital market.
• Consumer demand is challenged by inflation and a sluggish housing market.
• Masimo is exploring options for its consumer audio business, including a joint venture and a potential sale, with Morgan Stanley engaged to assist.
• The company let the exclusivity period with its JV partner expire on August 15th but continues discussions with them and other interested parties.
• The Board is evaluating all options to maximize shareholder value, including a JV, sale of the audio business, or separation of both businesses.
• Masimo raised its healthcare sales guidance, driven by improved census and strong contracting, with $234 million in net incremental new contracts in the first half.
• The company is targeting 7% to 10% long-range growth and aims to double earnings within the next 5 years.
• Driver shipments are expected to exceed 60,000 per quarter in the back half of the year.
• Gross margins are expected to improve, with a target of 30% operating margins in the long term.
• Masimo is involved in litigation with Apple and Politan Capital Management.
• The company's annual meeting is set for September 19, with a court hearing on September 9 regarding the Politan litigation.
• Masimo is cooperating with SEC and DOJ subpoenas related to the consumer business.
• The company is focused on leveraging investments to increase productivity and efficiency, aiming to reduce R&D expenses to closer to 8% of revenue longer term.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong performance in the healthcare segment and the potential for margin improvement. However, the ongoing proxy fight, litigation, and uncertainties surrounding the consumer business separation temper the overall outlook.

Positives

• Stable healthcare environment with strong census growth.
• Significant growth in consumables and service revenue.
• Strong contracting performance, setting up for future growth.
• Focus on improving gross margins and operating efficiency.
• Expansion into new markets and product lines, such as hemodynamic monitoring and ORi in the U.S.
• Targeting long-term growth and earnings improvement.
• The company is seeing encouraging trends in terms of driver shipments in the back half of the year.

Negatives

• Challenged consumer demand due to inflation and a sluggish housing market.
• Capital equipment sales are down 15% in the first half of the year.
• Ongoing litigation with Apple and Politan Capital Management.
• SEC and DOJ subpoenas related to the consumer business.
• The company is facing a proxy fight with Politan Capital Management, creating uncertainty.

Risks

• Macroeconomic weakness and potential recession impacting end market demand.
• Uncertainties surrounding the separation of the consumer business.
• Potential disruptions from the proxy fight and litigation.
• Dependence on census performance for healthcare revenue growth.
• Capital spending environment in hospitals remains soft.
• The company is facing risks associated with the litigation with Politan Capital Management.

Future Outlook

Masimo anticipates continued growth in its healthcare business, driven by strong contracting and census trends. The company is focused on improving margins and leveraging its investments to achieve long-term growth targets. The future of the consumer business is uncertain, pending the outcome of ongoing discussions and potential transactions.

Management Comments

• Micah Young, CFO, stated that the healthcare environment is stable with strong census growth.
• Management believes the fundamentals of the healthcare business are stronger than ever.
• Joe Kiani committed originally that he wanted to see 3 years. He has wanted to do it earlier.
• Management emphasized the risk of disrupting the company's momentum due to the proxy fight.

Industry Context

Masimo's focus on healthcare growth aligns with the broader trend of increasing demand for patient monitoring solutions. The company's expansion into new markets and product lines positions it to compete effectively in the evolving healthcare landscape. The potential separation of the consumer business reflects a strategic shift towards focusing on core strengths in the medical technology sector.

Comparison to Industry Standards

• Masimo's target of 30% operating margins is comparable to industry leaders like Intuitive Surgical and Edwards Lifesciences.
• The company's R&D spending target of 8% of revenue is in line with efficient operators in the medical device industry.
• Masimo's growth targets are ambitious but achievable given its strong market position and focus on innovation.
• The company's revenue per driver is expected to grow probably closer to 4% to 6% per year.

Legal Proceedings

• Masimo is involved in trade secret and patent infringement litigation against Apple.
• Masimo has filed a preliminary injunction seeking an order enjoining Quintin Koffey and Politan from voting against many of the proxies until they made corrections to their disclosures.
• The company is cooperating with SEC and DOJ subpoenas related to the consumer business.

Stakeholder Impact

• Shareholders face uncertainty due to the proxy fight and potential changes in company strategy.
• Employees may experience changes related to the potential separation of the consumer business.
• Customers can expect continued innovation and product development in the healthcare segment.
• Suppliers may be affected by changes in manufacturing locations and supply chain optimization.
• Creditors should monitor the company's financial performance and strategic decisions.

Next Steps

• Continue discussions regarding the potential separation of the consumer business.
• Await the outcome of the September 9 court hearing related to the Politan litigation.
• Hold the Annual Meeting on September 19.
• Cooperate with SEC and DOJ subpoenas.
• Execute plans to improve gross margins and operating efficiency.
• Launch ORi in the U.S.

Key Dates

Keywords

Masimo, healthcare, consumer audio, separation, joint venture, proxy fight, Politan, census, contracts, margins, litigation, drivers, consumables